Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events
for Obesity
11 locations incl. Walnut Creek
Sponsor: Novo Nordisk A/S
Sex: All·Age: 18+
Code: NCT07607587·Phase 1·Recruiting·Listed May 26, 2026